Tapentadol for chronic musculoskeletal pain in adults

Santos, João Pereira dos; Alarcão, Joana; Fareleira, Filipa; Vaz‐Carneiro, António; Costa, João

doi:10.1002/14651858.cd009923.pub2

Cited by 53 publications

(41 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high heterogeneity of the efficacy estimates may account for some of the suboptimal results. Nevertheless, TP PR confirmed the good tolerability profile with a 50% reduction in the risk of discontinuation due to side effects and a 9% reduction in the overall adverse events occurrence risk compared to oxycodone (42). Ongoing studies with promising results are also exploring the use of Tapentadol in the management of fibromyalgia not responding to standard therapy.…”

Section: Reviewmentioning

confidence: 72%

Chronic pain: the burden of disease and treatment innovations

Monti

Caporali

2015

Reumatismo

View full text Add to dashboard Cite

SUMMARYMusculoskeletal conditions are the most frequent cause of chronic pain and affect around 1 in 5 adults in Europe. When chronic pain occurs, it becomes disease itself, with substantial clinical, social and economic impact. Effi cacy and tolerability problems are encountered with all therapeutic strategies available to treat musculoskeletal pain. This often limits effective analgesia and patients' long term compliance, with the result that chronic pain is persistently underestimated and undertreated. Tapentadol is a novel, centrally acting analgesic that has been recently commercialized for the treatment of chronic pain. This new molecule, by combining two distinct mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), introduces a new pharmacological class called MOR-NRI. Several studies demonstrated promising results in the management of both nociceptive and neuropathic pain and good tolerability profi le, particularly concerning side effects, compared to traditional opioids. This novel analgesic represents a possible therapeutic option also in the rheumatologic fi eld, particularly in the treatment of osteoarthritis and low back pain.

show abstract

Section: Reviewmentioning

confidence: 72%

Chronic pain: the burden of disease and treatment innovations

Monti

Caporali

2015

Reumatismo

View full text Add to dashboard Cite

show abstract

“…Of these, the ones that have really led to treatment discontinuation were dizziness (2.6%), nausea (2.3%), vomiting (1.4%), drowsiness (1.3%) and headache (0.9%) 14,17 . Tapentadol was associated with the reduction of 50% in treatment discontinuation when compared with similar drugs 7 . On the other hand, there were more treatment discontinuations due to lack of effect than morphine, oxycodone, and fentanyl patch, but also fewer discontinuations due to the same reasons for placebo 25 .…”

Section: Contentsmentioning

confidence: 88%

“…It is in available in the U.S. since 2008 for the treatment of moderate acute to severe pain, in its immediate release (IR) formulation, and since 2011 for the treatment of moderate chronic to severe pain in its extended release (ER) formulation, after approval by the Food and Drug Administration (FDA) 5,6 . In the European market, the IR and ER formulations of the drug were approved by the European Medicines Agency (EMA) in 2010 7,8 . Its central analgesic action occurs by means of two mechanisms: 1) as an agonist of the μ-opioid receptors (MOR), with the same affinity or 10 times higher on KOR receptors (k-opioid receptor) REVIEW ARTICLE DOI 10.5935/2595-0118.20180015 and DOR (delta opioid receptor) 4 ; 2) as a norepinephrine reuptake inhibitor (NRI).…”

Section: Contentsmentioning

confidence: 99%

Tapentadol: what every doctor needs to know about this new drug

Mosele¹,

Almeida²,

Hess³

2018

Brazilian Journal of Pain

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES:Acute and chronic pain is a major problem with repercussion in our society, causing impairment in the quality of life of patients as well as socioeconomic losses, due to work absenteeism. This review aims to analyze the use of tapentadol, an analgesic not yet available in Brazil, with a dual mechanism of action, in the treatment of acute and chronic pain syndromes. CONTENTS: A review about this new drug was made on the Pubmed database using the keywords "tapentadol" and "opioids," evaluating its pharmacological and clinical aspects comparing with other current drugs in pain treatment, as well as its indications and contraindications in the management of patients with pain disorders. CONCLUSION: Tapentadol has been shown to be effective in the treatment of acute and chronic pain, with potency equivalent to the opioids currently used. In addition, it developed less tolerance, less adverse effects and better therapeutic response in chronic neuropathic pain when compared to pure μ-opioid receptors agonists. Keywords: Dual mechanism of action, Opioids, Tapentadol. RESUMO JUSTIFICATIVA E OBJETIVOS:A dor aguda e crônica consiste em um problema de grande repercussão em qualquer sociedade atual, causando degradação na qualidade de vida dos próprios pacientes e comprometimento socioeconômico pelo absenteísmo laboral. O objetivo deste estudo foi analisar o uso do tapentadol, um analgésico ainda não disponível no Brasil e com duplo mecanismo de ação, no tratamento das síndromes dolorosas agudas e crônicas. Tapentadol: what every doctor needs to know about this new drug CONTEÚDO:Foi realizada uma pesquisa na base de dados Pubmed utilizando os descritores "tapentadol" e "opioides" para revisão da literatura mundial sobre esse novo fármaco, avaliando as características farmacológicas e aspectos clínicos do seu uso na realidade atual, em comparação com os fármacos já existentes no mercado, assim como suas indicações e contraindicações no manuseio do paciente com dor. CONCLUSÃO: O tapentadol se mostrou eficaz no tratamento de dores agudas e crônicas, com potência equiparável aos opioides já comercializados. Além disso, desenvolveu menos tolerân-cia, menos efeitos adversos e melhor resposta terapêutica na dor crônica neuropática quando comparado com agonistas receptores opioides tipo μ puros. Descritores: Duplo mecanismo de ação, Opioides, Tapentadol. INTRODUCTIONPain is a problem of great proportion, involving 20 to 25% of the population with an increasing incidence. Despite the extraordinary advances in anatomy, physiology, diagnosis and pain management, more than 50% of patients report improper relief. This can be related to the neuroplasticity process of the pain pathways 1 , creating a persistent "memory" of the aggressive event and neuronal hiperexcitability 2,3 . Understanding chronic pain neurobiology is fundamental to target the treatment. Thus, the use of drugs that act on more than one pathophysiologic mechanism, as tapentadol, can be a new weapon in the therapeutic armamentarium aga...

show abstract

“…Так, в последние годы в клиническую практику внедряются новые средства этого ряда, обладающие хорошей эффективностью и прием-лемым уровнем безопасности, например тапентадол, сочета-ющий в себе свойства агониста опиоидных рецепторов и СИОЗС [27,28]. Однако опиоиды, которые прекрасно об-легчают сильнейшую боль, вызванную хирургическими вме-шательствами и острыми травмами, не столь эффективны при хронической СМБ.…”

Section: %unclassified

Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution

Каратеев¹

2017

RJTAO

View full text Add to dashboard Cite

Идеальная стратегия терапии любого заболевания предполагает этиотропный и патогенетический подход. Всегда следует искать причину болезни (например, если ее развитие вызвано инфекционным агентом), а когда это не-возможно (как в подавляющем большинстве случаев при хронических заболеваниях), четко выделить основные зве-нья ее патогенеза. Точное знание направления фармакоте-рапии ориентирует на очень высокий результат, которого можно достичь в процессе лечения: полное прекращение прогрессирования болезни, т. е. стойкая медикаментозная, а при благоприятном стечении обстоятельств и безмедика-ментозная ремиссия или даже полное выздоровление. (non-steroidal anti-inflammatory drugs (NSAIDs), opioids, local glucocorticoid injections, duloxetine, etc.) Effective control of musculoskeletal pain (MSP) is one of the main tasks of medical care for the most common rheumatic diseases, such as osteoarthritis (OA) and non-specific back pain (NSBP). Epidemiological surveys have shown that a substantial proportion (about 40-50%) of patients consider their assigned treatment to be ineffective and are dissatisfied with its results. The reasons for this are a phenotypic diversity of MSP, individual responses to analgesic drugs, and comorbidities (particularly metabolic disorders and depression). Placebo-controlled trials have demonstrated that monotherapy with the most popular drugs

show abstract

Tapentadol for chronic musculoskeletal pain in adults

Cited by 53 publications

References 48 publications

Chronic pain: the burden of disease and treatment innovations

Chronic pain: the burden of disease and treatment innovations

Tapentadol: what every doctor needs to know about this new drug

Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution

Contact Info

Product

Resources

About